Jeffrey Barrett

Jeffrey Barrett
Director, Open Targets
Jeffrey Barrett has been involved in Open Targets since it launched as the CTTV in 2014, and began his role as Director on 1 May 2015. Jeff is a statistical geneticist who has led several of the largest genome-wide association studies of complex disease. He first became interested in human genetics in Mark Daly’s lab at the Whitehead Institute before moving to Lon Cardon’s group in Oxford, where he received a D. Phil in statistical genetics. Jeff was an analyst in the Wellcome Trust Case Control Consortium, and led early GWAS meta-analyses in inflammatory bowel disease and type 1 diabetes while a postdoc with David Clayton in Cambridge. Since joining the Sanger Institute as a group leader in 2008, he has used next-generation sequencing in thousands of individuals to find variation associated with both rare and common human diseases.

Tel:+ 44 (0) 1223 49 2351 / Fax:

http://www.targetvalidation.org/leadership (personal homepage)

Open Targets

Open Targets aims to provide evidence on the biological validity of therapeutic targets and provide an initial assessment of the likely effectiveness of pharmacological intervention on these targets, using genome-scale experiments and analysis. Open Targets aims to provide an R&D framework that applies to all aspects of human disease, and to share its data openly with the scientific community.

The goal of Open Targets is to provide an R&D framework that applies to all aspects of human disease, and to share its data openly with the scientific community. It is a shared initiative between the European Bioinformatics Institute (EMBL-EBI), a global leader in the management, integration and analysis of public domain life science data; GSK, a leading, global pharmaceutical company; Biogen, one of the world’s oldest independent biotechnology companies; and the Wellcome Trust Sanger Institute, a world-leading genomics institution with expertise in human genetics, cancer and infectious disease. Open Targets exists as a core operation within the Innovation Centre of EMBL-EBI's South Building on the Wellcome Genome Campus and involves staff from each of the institutions directly interacting there with access to the full normal scientific life of the campus. In addition it draws upon expertise from groups within the institutions spreading connections across the sites.

Publications

Loading...

Team members

  • Miguel Carmona
  • Denise Carvalho-Silva
  • Ian Dunham
  • Holly Foster
  • Hanna Najgebauer
  • ChuangKee Ong
  • Andrea Pierleoni
  • JEREMY SCHWARTZENTRUBER
  • Michaela Spitzer
  • Beata Wyspianska